تفاصيل الوثيقة
|
نوع الوثيقة |
: |
مقال في مجلة دورية |
|
عنوان الوثيقة |
: |
استخدام علاج البريقابالين لعلاج صرع الأطفال المستعصى Pregabalin: preliminary experience in intractable childhood epilepsy. |
|
لغة الوثيقة |
: |
الانجليزية |
|
المستخلص |
: |
Pregabalin is a new antiepileptic drug that acts at presynaptic calcium channels, modulating neurotransmitter release. We report our experience in treating consecutive children with severe drug resistant epilepsy in a prospective, open label, add on trial. Nineteen children (63% males) aged 4-15 years (mean 9.7, SD 2.9) were included. Most children (74%) had daily seizures that failed multiple drugs (mean 5). The epilepsy was symptomatic in 58%, and 74% had associated cognitive deficits. The seizures were mixed in 9 (47%) and 4 (21%) had Lennox Gastaut syndrome. Pregabalin was maintained at 150-300 mg/day. On pregabalin, 1 (6%) child became seizure free and 7 (37%) had >50% seizure reduction. The percentage of children with daily seizure was reduced from 74% before pregabalin to 37% afterward (p <0.002). Side effects were noted in 6 (32%) with somnolence, weight gain, dizziness, or behavioral change. The drug had to be withdrawn in 5 (26%) children for of lack of efficacy and in 2 (11%) for worsening of myoclonic epilepsy. We conclude that pregabalin is a useful addition in the treatment of refractory childhood epilepsy. The drug should be used with caution in myoclonic epilepsy. Controlled studies are needed to establish long term efficacy and tolerability. |
|
ردمد |
: |
0930-2794 |
|
اسم الدورية |
: |
Pediatric Neurology |
|
المجلد |
: |
5 |
|
العدد |
: |
40 |
|
سنة النشر |
: |
2009 هـ
2009 م |
|
نوع المقالة |
: |
مقالة علمية |
|
تاريخ الاضافة على الموقع |
: |
Wednesday, March 10, 2010 |
|
الباحثون
| محمد جان | jan, Mohammed | باحث | دكتوراه | |
|
الرجوع إلى صفحة الأبحاث
|